19395-87-0
19395-87-0
Chemical Structure
SC-19220
- CAS No.: 19395-87-0
- Formula:C16H14ClN3O3
- Molecular Weight:331.75
IUPAC Name: N'-acetyl-8-chlorodibenzo[b,f][1,4]oxazepine-10(11H)-carbohydrazide
InChIKey: KNURFLJTOUGOOQ-UHFFFAOYSA-N
SMILES: O=C(N1C2=CC(Cl)=CC=C2OC3=C(C1)C=CC=C3)NNC(C)=O
Biological Activity: SC-19220 is a prostaglandin E2 receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SC-19220 | 99.86% | SC-19220 is a prostaglandin E2 receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SC-19220 (Standard) | ≥98% | SC-19220 (Standard) is the analytical standard of SC-19220 (HY-102065). This product is intended for research and analytical applications. SC-19220 is a prostaglandin E2 receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Inoue H, et al. SC-19220, a prostaglandin E2 antagonist, inhibits osteoclast formation by 1,25-dihydroxyvitamin D3 in cell cultures. J Endocrinol. 1999;161(2):231-236. [Content Brief]
- [2]. Tsujisawa T, et al. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL. J Bone Miner Res. 2005;20(1):15-22. [Content Brief]
- [3]. Bennett A, et al. Antagonism of prostanoid-induced contractions of rat gastric fundus muscle by SC-19220, sodium meclofenamate, indomethacin or trimethoquinol. Br J Pharmacol. 1980;71(1):169-175. [Content Brief]
